HDAC9 and cancer: Specific HDAC inhibitors have been shown to disrupt cancer cell proliferation through processes including interruption of DNA repair through non-homologous end-joining (NHEJ) [13], upregulation of pro-apoptotic Bcl2-member (BIM) [16], and degradation of FLT3 signaling in Akt, ERK, and STAT5 pathways.